Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large <i>post hoc</i> analysis of five phase III clinical trials
Belimumab is superior to placebo in inducing improvement and in preventing flares in the mucocutaneous domain of SLE, especially in patients with high disease activity and in serologically active patients.
Authors
- Julius Lindblom
- Nefeli Giannopoulou
- Dionysis Nikolopoulos (ORCID: https://orcid.org/0000-0002-9894-6966)
- Alexander Tsoi (ORCID: https://orcid.org/0009-0004-4815-7477)
- Giorgia Grosso (ORCID: https://orcid.org/0009-0005-0624-7009)
- Ioannis Parodis (ORCID: https://orcid.org/0000-0002-4875-5395)
- Nurşen Çetrez (ORCID: https://orcid.org/0000-0001-9874-841X)
Institutions
- Karolinska University Hospital (SE)
- Örebro University (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1093/rheumatology/keaf145
- Citations
- 5
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 8.34